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Science Versus Stigma
Stigma is an enormous obstacle to more effective drug
abuse treatment. Widespread perceptions that addic-
tion strips individuals of basic human qualities lead to self-
fulfilling predictions that those who are addicted cannot
recover or ever play positive and productive social roles.
Two articles in this issue of Addiction Science & Clinical
Practice illustrate a fundamental truth about stigma: It
arises when we do not understand the true nature of a
health condition.
Dr. Michael Dennis and Dr. Christy K Scott, in a thor-
ough presentation of the reasons for managing addiction
as a chronic disease, enumerate some of the consequences
of regarding it, instead, as an acute problem. These include
demoralized patients, frustrated clinicians and families,
and a treatment armamentarium that is often ill-suited to
deal with the challenges in long-term recovery. Dr. Diana
Sylvestre argues that the pervasive fear of hepatitis C is
excessive. She reports that misperceptions cause some
patients to despair and avoid seeking treatment, and some
treatment providers to believe—incorrectly—that treat-
ing drug abusers with this disease is futile.
Historically, stigma wanes when people understand
why and how a disease develops. Striking examples include
the conceptual rehumanizing of people with leprosy and
epilepsy when science accounted for those diseases’
disturbing manifestations.
Today, researchers and informed, creative clinicians
are achieving the understanding and management skills
that eventually will erase the stigma surrounding drug
addiction. We are witnessing another instance of one of
the great moral achievements of science: establishing the
right of people who have been regarded as hopeless or
untouchable to full consideration as human beings.
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